Quick Positive Results For RNA-Based Pfizer And BioNTech CoVID-19 Vaccine Doesn't Mean It Was Rushed
Recently, Pfizer and BioNTech released promising preliminary results of their clinical Phase III trials with 40,000 participants for their RNA vaccine candidate. This report suggests 90% efficacy for protection against SARS-CoV-2, the virus which causes the CoVID-19 disease. However, there is no peer-reviewed publication on this yet.
